Harold Szerlip, MD
Nephrology · Charleston, SCNPI 1942394432
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $142,673 of the $229,080 with a category attached, or 62.3%. AstraZeneca accounts for 65.6% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $108,589 and has fallen 92.9% since, to $7,702 in 2025. Among nephrology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 402 payments — averaging $569.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$150K
- La Jolla Pharmaceutical Company$41K
- Travere Therapeutics, Inc.$21K
- GSK$6K
- Calliditas Therapeutics US Inc.$3K
- Vifor Pharma, Inc.$2K
- plus $6K from 18 others
Across 88 payments — averaging $2430.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$66K
- Boehringer Ingelheim Pharma GmbH & Co.kg$43K
- AstraZeneca$37K
- Travere Therapeutics, Inc.$29K
- Bayer$21K
- Akebia Therapeutics Inc$18K
What the payments were for
- Consulting fees$55,64524%
- Speaking & faculty fees$142,67362%
- Travel & lodging$21,4809%
- Food & beverage$9,1114%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 242 | $150,187 |
| La Jolla Pharmaceutical Company | 55 | $40,932 |
| Travere Therapeutics, Inc. | 30 | $21,465 |
| GSK | 4 | $5,750 |
| Calliditas Therapeutics US Inc. | 6 | $3,400 |
| Vifor Pharma, Inc. | 8 | $1,809 |
| Echonous, Inc. | 1 | $1,804 |
| Boehringer Ingelheim International GmbH | 7 | $1,562 |
| Johnson & Johnson | 7 | $479 |
| Amarin Pharma, Inc. | 1 | $375 |
| Nxstage Medical, Inc. | 11 | $330 |
| OPKO Pharmaceuticals, LLC | 7 | $164 |
| Veloxis Pharmaceuticals, Inc. | 7 | $152 |
| Otsuka America Pharmaceutical, Inc. | 4 | $146 |
| Novartis | 1 | $113 |
| Aurinia Pharma U.S., Inc. | 1 | $108 |
| Chiesi USA, Inc. | 2 | $95 |
| Mallinckrodt Enterprises LLC | 2 | $44 |
| ANI Pharmaceuticals, Inc. | 1 | $40 |
| Baxter Healthcare | 1 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Kaneka Medical America LLC | 1 | $25 |
| Bayer | 1 | $23 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$229,080 in reported general payments places this provider in the 95th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 71 | $44,333 |
| FarxigaDapagliflozin Propanediol | 46 | $33,328 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $10,932 |
| MyrbetriqMirabegron | 11 | $5,258 |
| Losartan Potassium | 61 | $795 |
| Telmisartan | 12 | $564 |
| Amlodipine Besylate | 38 | $310 |
| Chlorthalidone | 17 | $266 |
| Olmesartan Medoxomil | 25 | $254 |
| Furosemide | 25 | $235 |
| Bumetanide | 11 | $231 |
| Allopurinol | 29 | $216 |
| Torsemide | 21 | $198 |
| Carvedilol | 17 | $164 |
| Lisinopril | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $150,187 | $44,26060 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Charleston
- Joshua LipschutzCharleston$44K
- Charles BunkeCharleston$39K
- Anand AchantiCharleston$38K
- Blaithin McMahonCharleston$11K
- Michael MadaioCharleston$10K
- Roberto PisoniCharleston$7K
- Michael CaseyCharleston$5K
- Rohan KatariaCharleston$4K
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.